The Relationship Between Tumor Inflammatory Cell Infiltrate and Outcome in Patients with Pancreatic Ductal Adenocarcinoma

被引:58
作者
Jamieson, Nigel B. [1 ,2 ]
Mohamed, Mohamed [2 ]
Oien, Karin A. [3 ]
Foulis, Alan K. [3 ]
Dickson, Euan J. [1 ]
Imrie, Clem W. [1 ]
Carter, C. Ross [1 ]
McKay, Colin J. [1 ]
McMillan, Donald C. [2 ]
机构
[1] Glasgow Royal Infirm, W Scotland Pancreat Unit, Glasgow G4 0SF, Lanark, Scotland
[2] Glasgow Royal Infirm, Univ Dept Surg, Glasgow G4 0SF, Lanark, Scotland
[3] Glasgow Royal Infirm, Univ Dept Pathol, Glasgow G4 0SF, Lanark, Scotland
关键词
PROGNOSTIC VALUE; SYSTEMIC INFLAMMATION; CURATIVE RESECTION; T-CELLS; CANCER; SURVIVAL; LYMPHOCYTES; CACHEXIA; SCORE; MANAGEMENT;
D O I
10.1245/s10434-012-2370-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The tumor-associated inflammatory cell infiltrate is recognized to have prognostic value in various common solid tumors. However, the prognostic value of the tumor inflammatory cell infiltrate has not been established in pancreatic ductal adenocarcinoma (PDAC) nor has its relationship with the systemic inflammatory response. Retrospective study was made of 173 patients who underwent surgery between 1997 and 2009. Routine pathology specimens were scored according to density of the tumor inflammatory cell infiltrate, and biochemical data were collected preoperatively. Low-grade tumor inflammatory cell infiltrate was associated with earlier tumor recurrence (P < 0.001) and particularly in the liver (P = 0.027). It was also associated with T3 tumors (P < 0.05), lymph node involvement (P < 0.05), and resection margin involvement (P < 0.05). On univariate survival analysis, age < 65 years (P < 0.05), mGPS (P < 0.001), increased tumor stage (P < 0.01), nodal involvement (P < 0.01), size (P < 0.05), grade (P < 0.05), perineural invasion (P < 0.05), venous invasion (P < 0.01), resection margin involvement (P a parts per thousand currency sign 0.001), vascular reconstruction (P < 0.05), and no adjuvant chemotherapy (P < 0.05) were associated with poor survival. In contrast, high-grade tumor inflammatory cell infiltrate was associated with better survival (P < 0.001). On multivariate survival analysis, mGPS [hazard ratio (HR): 1.77, 95 % confidence interval (95 % CI): 1.19-2.62, P = 0.005], tumor stage (HR: 2.21, 95 % CI: 1.16-4.23, P = 0.016), resection margin involvement (HR: 2.19, 95 % CI: 1.41-3.44, P = 0.001), venous invasion (HR: 1.79, 95 % CI: 1.22-2.63, P = 0.003), tumor inflammatory cell infiltrate (HR: 0.37, 95 % CI: 0.25-0.55, P = 0.0001), and adjuvant chemotherapy (P = 0.04) were independently prognostic. The results of the study show, for the first time, that the presence of a high-grade tumor inflammatory cell infiltrate is an independent predictor of prolonged overall survival following resection for PDAC. Furthermore, measures of the local and the systemic inflammatory response were inversely associated.
引用
收藏
页码:3581 / 3590
页数:10
相关论文
共 46 条
[1]  
[Anonymous], 2002, AJCC cancer staging manual, V6th, P157
[2]   CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans [J].
Beatty, Gregory L. ;
Chiorean, Elena G. ;
Fishman, Matthew P. ;
Saboury, Babak ;
Teitelbaum, Ursina R. ;
Sun, Weijing ;
Huhn, Richard D. ;
Song, Wenru ;
Li, Dongguang ;
Sharp, Leslie L. ;
Torigian, Drew A. ;
O'Dwyer, Peter J. ;
Vonderheide, Robert H. .
SCIENCE, 2011, 331 (6024) :1612-1616
[3]  
Campbell F, 2002, STANDARDS MINIMUM DA
[4]   Dynamics of the immune reaction to pancreatic cancer from inception to invasion [J].
Clark, Carolyn E. ;
Hingorani, Sunil R. ;
Mick, Rosemarie ;
Combs, Chelsea ;
Tuveson, David A. ;
Vonderheide, Robert H. .
CANCER RESEARCH, 2007, 67 (19) :9518-9527
[5]  
Clemente CG, 1996, CANCER, V77, P1303, DOI 10.1002/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO
[6]  
2-5
[7]   Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability [J].
Colotta, Francesco ;
Allavena, Paola ;
Sica, Antonio ;
Garlanda, Cecilia ;
Mantovani, Alberto .
CARCINOGENESIS, 2009, 30 (07) :1073-1081
[8]   C-reactive protein - An activator of innate immunity and a modulator of adaptive immunity [J].
Du Clos, TW ;
Mold, C .
IMMUNOLOGIC RESEARCH, 2004, 30 (03) :261-277
[9]   Cancer immunoediting: from immunosurveillance to tumor escape [J].
Dunn, GP ;
Bruce, AT ;
Ikeda, H ;
Old, LJ ;
Schreiber, RD .
NATURE IMMUNOLOGY, 2002, 3 (11) :991-998
[10]   The three Es of cancer immunoediting [J].
Dunn, GP ;
Old, LJ ;
Schreiber, RD .
ANNUAL REVIEW OF IMMUNOLOGY, 2004, 22 :329-360